A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma
Authors
Keywords
-
Journal
Future Oncology
Volume 14, Issue 4, Pages 319-329
Publisher
Future Medicine Ltd
Online
2017-11-02
DOI
10.2217/fon-2017-0371
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood
- (2018) Kazunori Murata et al. CLINICAL BIOCHEMISTRY
- Is immunotherapy here to stay in multiple myeloma?
- (2017) Paula Rodríguez-Otero et al. HAEMATOLOGICA
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
- (2017) S K Kumar et al. LEUKEMIA
- Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials
- (2017) Jean-Samuel Boudreault et al. Expert Review of Hematology
- Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)
- (2017) Jinghua Liu et al. Oncotarget
- A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?
- (2017) Damian J. Green et al. Current Hematologic Malignancy Reports
- Is immunotherapy here to stay in multiple myeloma?
- (2017) Paula Rodríguez-Otero et al. HAEMATOLOGICA
- Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
- (2016) A. Jakubowiak et al. BLOOD
- Myeloid-derived suppressor cells: The green light for myeloma immune escape
- (2016) Ehsan Malek et al. BLOOD REVIEWS
- Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma
- (2016) María-Victoria Mateos et al. BRITISH JOURNAL OF HAEMATOLOGY
- New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
- (2016) P. Neri et al. CLINICAL CANCER RESEARCH
- Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study
- (2016) Jesus Berdeja et al. Clinical Lymphoma Myeloma & Leukemia
- Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma
- (2016) Leonid Gibiansky et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)
- (2016) Cesarina Giallongo et al. Oncotarget
- Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment
- (2015) A. Ponzetta et al. CANCER RESEARCH
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study
- (2015) Paul G Richardson et al. Lancet Haematology
- Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
- (2014) Balaji Balasa et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization
- (2014) Luis-Alberto Pérez-Quintero et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells
- (2014) Huaijian Guo et al. MOLECULAR AND CELLULAR BIOLOGY
- Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
- (2014) Niccolo Bolli et al. Nature Communications
- Immunological Dysregulation in Multiple Myeloma Microenvironment
- (2014) Alessandra Romano et al. Biomed Research International
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma
- (2013) André Veillette et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
- (2012) J. B. Egan et al. BLOOD
- Clonal competition with alternating dominance in multiple myeloma
- (2012) J. J. Keats et al. BLOOD
- Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
- (2012) R. J. Pessoa de Magalhaes et al. HAEMATOLOGICA
- Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
- (2012) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
- (2010) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- (2009) F. van Rhee et al. MOLECULAR CANCER THERAPEUTICS
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now